Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

NCT01498484 is registered in ClinicalTrials.gov with Atara Biotherapeutics as lead sponsor.

NCT NCT01498484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01498484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Lead sponsor
Atara Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
July 31, 2019
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebv-associated malignancies, ebv-induced lymphomas, transplant patients with ebv viremia at high risk for developing a recurrent ebv lymphoma